Company Profile
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Latest News
How Do the Vanguard S&P 500 Growth ETF and the State Street Small Cap Growth ETF Compare?
Earnings Calendar and Analysis for This Week (July 27-31)
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.alkermes.com |
| Audit Risk | 3 |
| Board Risk | 5 |
| Overall Risk | 3 |
| Market Cap | 8.82B |
| Trailing P/E | 58.77 |
| Forward P/E | 32.29 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | 0.9 |
| Forward EPS | 1.64 |
| Book Value | 10.52 |
| Price-to-Book | 5.03 |
| Enterprise-to-Revenue | 6.33 |
| Enterprise-to-EBITDA | 35.48 |
| Short Ratio | 5.71 |
| Earnings Date | 07/28/2026 |
| Earnings Call Date | 07/28/2026 |
| Earnings Average | 0.29 |
| Earnings Low | -0.07 |
| Earnings High | 0.64 |
| Revenue Average | 457.36M |
| Revenue Low | 435.90M |
| Revenue High | 481.70M |